IBLIAS

This brand name is authorized in Estonia, Lithuania, Poland

Active ingredients

The drug IBLIAS contains one active pharmaceutical ingredient (API):

1 Octocog alfa
UNII P89DR4NY54 - ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT

Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Read about Coagulation factor VIII

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
B02BD02 Coagulation factor VIII B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1713327, 1713338, 1713349, 1713350, 1713361
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1079703, 1079704, 1079705, 1079706, 1079707
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100367097, 100367105, 100367111, 100367128, 100367134

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.